Loss of both diffusion restriction and arterial enhancement can predict complete pathological response following Y-90 selective internal radiation therapy for hepatocellular carcinoma
Abdominal Radiology · 2026
DOI: 10.1007/s00261-026-05377-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Abdominal Radiology, 2026. Verfasst von Kah Heng Alexander Lim und 11 weiteren Autor:innen. Beteiligte Einrichtung: Sir Charles Gairdner Hospital, Nedlands, Australia. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Yttrium Radioisotopes, Diffusion Magnetic Resonance Imaging. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sir Charles Gairdner Hospital.
Abstract (Originalsprache)
Purpose
To assess the association of diffusion restriction on diffusion weighted MRI (DWI) with complete pathological necrosis (CPN) in hepatocellular carcinoma (HCC) following selective internal radiation therapy with Yttrium-90 resin microspheres (SIRT).
Methods
A retrospective cohort study of patients undergoing resection or transplantation for HCC following SIRT was performed. Imaging pre- and post-SIRT was assessed for response to treatment via mRECIST and for the presence of diffusion restriction on DWI. Histological specimens were assessed for complete pathological necrosis (CPN).
Results
Twenty-nine tumours were included from 25 patients; mRECIST complete response (CR) demonstrated moderate reliability (sensitivity 0.92, specificity 0.68) for predicting CPN. Twelve tumours did not have diffusion restriction on pretreatment DWI; following their exclusion, loss of diffusion restriction demonstrated a weak agreement (sensitivity 0.85, specificity 0.80, Cohen’s Kappa 0.197) for prediction of CPN. The combination of mRECIST CR and loss of diffusion restriction was associated with CPN in 100% (6/6) cases; whilst persistent abnormal diffusion restriction despite mRECIST CR was associated with residual disease in 75% (3/4) cases.
Conclusion
The combination of mRECIST CR when combined with loss of diffusion restriction appears to predict CPN post SIRT; persistent diffusion restriction despite the findings of mRECIST CR appears to correlate with residual disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sir Charles Gairdner Hospital, Nedlands, Australia.
- University of Western Australia, Perth, Australia.
- Pathwest Laboratory Medicine, Nedlands, Australia.
- Fiona Stanley Hospital, Perth, Australia.
- Sir Charles Gairdner Hospital, Nedlands, Australia. lingjun.mou@gmail.com.
- University of Western Australia, Perth, Australia. lingjun.mou@gmail.com.
Förderung
- Sir Charles Gairdner Hospital
Zitieren
APA
Lim, K. H. A., Clifford, M. J., Ormiston, W., Khor, T. S., Ngo, K. Q. S., Rowcroft, A., Mou, L., Delriviere, L., Wallace, M., Bhandari, M., Ballal, M., & Tibballs, J. (2026). Loss of both diffusion restriction and arterial enhancement can predict complete pathological response following Y-90 selective internal radiation therapy for hepatocellular carcinoma. Abdominal Radiology. https://doi.org/10.1007/s00261-026-05377-5
Vancouver
Lim KHA, Clifford MJ, Ormiston W, Khor TS, Ngo KQS, Rowcroft A, et al. Loss of both diffusion restriction and arterial enhancement can predict complete pathological response following Y-90 selective internal radiation therapy for hepatocellular carcinoma. Abdominal Radiology. 2026. doi:10.1007/s00261-026-05377-5
BibTeX
@article{Lim2026,
author = {Lim, Kah Heng Alexander and Clifford, Matthew Joel and Ormiston, William and Khor, Tze Sheng and Ngo, Khanh Quoc Steven and Rowcroft, Alistair and Mou, Lingjun and Delriviere, Luc and Wallace, Michael and Bhandari, Mayank and Ballal, Mohammad and Tibballs, Jonathan},
title = {Loss of both diffusion restriction and arterial enhancement can predict complete pathological response following Y-90 selective internal radiation therapy for hepatocellular carcinoma},
journal = {Abdominal Radiology},
year = {2026},
doi = {10.1007/s00261-026-05377-5}
}
EUVIMED